Wrzos Claudia, Winkler Anne, Metz Imke, Kayser Dieter M, Thal Dietmar R, Wegner Christiane, Brück Wolfgang, Nessler Stefan, Bennett Jeffrey L, Stadelmann Christine
Institute of Neuropathology, University Medical Centre Göttingen, Robert-Koch-Str. 40, 37099, Göttingen, Germany.
Acta Neuropathol. 2014 Apr;127(4):523-38. doi: 10.1007/s00401-013-1220-8. Epub 2013 Nov 30.
Neuromyelitis optica (NMO) is a chronic, mostly relapsing inflammatory demyelinating disease of the CNS characterized by serum anti-aquaporin 4 (AQP4) antibodies in the majority of patients. Anti-AQP4 antibodies derived from NMO patients target and deplete astrocytes in experimental models when co-injected with complement. However, the time course and mechanisms of oligodendrocyte loss and demyelination and the fate of oligodendrocyte precursor cells (OPC) have not been examined in detail. Also, no studies regarding astrocyte repopulation of experimental NMO lesions have been reported. We utilized two rat models using either systemic transfer or focal intracerebral injection of recombinant human anti-AQP4 antibodies to generate NMO-like lesions. Time-course experiments were performed to examine oligodendroglial and astroglial damage and repair. In addition, oligodendrocyte pathology was studied in early human NMO lesions. Apart from early complement-mediated astrocyte destruction, we observed a prominent, very early loss of oligodendrocytes and oligodendrocyte precursor cells (OPCs) as well as a delayed loss of myelin. Astrocyte repopulation of focal NMO lesions was already substantial after 1 week. Olig2-positive OPCs reappeared before NogoA-positive, mature oligodendrocytes. Thus, using two experimental models that closely mimic the human disease, our study demonstrates that oligodendrocyte and OPC loss is an extremely early feature in the formation of human and experimental NMO lesions and leads to subsequent, delayed demyelination, highlighting an important difference in the pathogenesis of MS and NMO.
视神经脊髓炎(NMO)是一种慢性、多为复发型的中枢神经系统炎性脱髓鞘疾病,大多数患者血清中存在抗水通道蛋白4(AQP4)抗体。在实验模型中,与补体共同注射时,源自NMO患者的抗AQP4抗体靶向并消耗星形胶质细胞。然而,少突胶质细胞丢失和脱髓鞘的时间进程及机制,以及少突胶质细胞前体细胞(OPC)的命运尚未得到详细研究。此外,也没有关于实验性NMO病变中星形胶质细胞再填充的研究报道。我们利用两种大鼠模型,通过全身转移或脑内局部注射重组人抗AQP4抗体来产生类似NMO的病变。进行时间进程实验以检查少突胶质细胞和星形胶质细胞的损伤与修复。此外,还对早期人类NMO病变中的少突胶质细胞病理学进行了研究。除了早期补体介导的星形胶质细胞破坏外,我们还观察到少突胶质细胞和少突胶质细胞前体细胞(OPC)在极早期显著丢失,以及髓鞘延迟丢失。局灶性NMO病变中的星形胶质细胞在1周后已大量再填充。Olig2阳性的OPC在NogoA阳性的成熟少突胶质细胞之前重新出现。因此,通过两种紧密模拟人类疾病的实验模型,我们的研究表明少突胶质细胞和OPC丢失是人类和实验性NMO病变形成过程中的一个极早期特征,并导致随后的延迟性脱髓鞘,突出了多发性硬化症(MS)和NMO发病机制的一个重要差异。